An Israeli biotechnology firm is harvesting stem cells from human
placentas that appear to successfully treat multiple sclerosis,
diabetes, alcoholism, and even sports-related injuries. Pluristem
Therapeutics processes stem cells obtained from donors' placentas into
a variety of ready-to-use medications, which is more than just cool
science--it's also an indication of where biotech will be headed over
the next decade.
Pluristem CEO Zami Aberman told Fast Company that the stem cells
obtained from "one placenta can help treat 10,000 people." The
company's latest project is a preclinical trial at New York University
to test whether placenta-derived stem cells can be used to treat
diabetic foot ulcers. Diabetic foot ulcers occur in more than 10% of
all patients with the disease and frequently lead to amputation.
Doctors at NYU are hoping that the stem cells can help successfully
grow new blood vessels from pre-existing blood vessels in patients'
feet and to help aid in tissue regeneration. <snip>
As I said much earlier, we have to keep moving because our competition
is moving, too. And we have to watch left field.